LENA BCR-ABL1 Genotyping Kit is a qualitative in vitro diagnostic test for differentiating of BCR-ABL1 p210, BCR-ABL1 p190, BCR-ABL1 p230 three splice variants with leukemia. The kit detects RNA transcripts of fusion genes extracted from human bone marrow or whole blood samples with BCR-ABL1. The results obtained from the kit provides more information of BCR-ABL1 to professionals for comprehensive consideration associated with patient condition, drug indication, therapeutic response and other detection findings.
BCR-ABL1 P190 Kit is intended to quantify the BCR-ABL1 P190 transcripts in human bone marrow or whole blood samples of leukemia patients. The results obtained from the kit provides information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
BCR-ABL1 P210 Kit is intended to quantify the BCR-ABL1 P210 transcripts in human bone marrow or whole blood samples of leukemia patients. The results obtained from the kit provides information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
The results obtained from the kits provides more information to professionals for comprehensive consideration associated with patient condition, drug indication, therapeutic response and other detection findings. The results obtained from the kits provide information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
PML-RARΑ L Detection Kit is intended to quantify the PML-RARα L transcripts in human bone marrow or whole blood samples of leukemia patients.
PML-RARΑ S Detection Kit is intended to quantify the PML-RARα S transcripts in human bone marrow or whole blood samples of leukemia patients.
PML-RARΑ V Detection Kit is intended to quantify the PML-RARα V transcripts in human bone marrow or whole blood samples of leukemia patients.
PML-RARα Genotyping Kit is a qualitative in vitro diagnostic test for differentiating of PML-RARα L, PML-RARα S and PML-RARα V three splice variants with leukemia. The kit detects RNA transcripts of fusion genes extracted from human bone marrow or whole blood samples with PML-RARα.
The results obtained from the kit provides information about efficiency of treatment or Minimal Residual Disease (MRD) in patients.
